You are leaving this website
By clicking this link, you will be leaving the NERLYNX website and will be redirected to another webpage.
SHE’S WORKED HARD TO GET THIS FAR. CONTINUE TO TAKE EVERY OPPORTUNITY TO TREAT HER2+ DISEASE.
Real patient with HER2+ HR+ breast cancer. Not treated with NERLYNX.
Photograph taken April 2013.
*In patients randomized to NERLYNX ≤1 year from completing trastuzumab-based therapy. Results of ExteNET are supported by descriptive analyses after 5 years of follow-up, with 74.5% (2117/2840) of patients reconsented. 95% of the HR+ study population received concurrent endocrine therapy. Recurrence is defined as time from randomization to first occurrence of invasive ipsilateral tumor recurrence, invasive contralateral breast cancer, local/regional invasive recurrence, distant recurrence, or death from any cause.
†5.1% absolute benefit in invasive disease-free survival vs placebo at 5 years in early-stage HER2+ HR+ breast cancer patients who were randomized within 1 year of completing trastuzumab-based therapy (HR=0.58; 95% CI: 0.41, 0.82; 2-sided P=0.002).
‡Median PFS of 5.6 months with NERLYNX + capecitabine vs 5.5 months with lapatinib + capecitabine (HR=0.76; 95% CI: 0.63, 0.93; P=0.0059).
CI: confidence interval; eBC: early breast cancer; HER: human epidermal growth factor receptor; HR: hazard ratio; HR+: hormone receptor–positive; mBC: metastatic breast cancer; PFS: progression-free survival.
Learn about dose modifications, diarrhea management, and drug interactions with NERLYNX.
Select IMPORTANT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS:
Please see additional IMPORTANT SAFETY INFORMATION below.
IMPORTANT SAFETY INFORMATION
NERLYNX® (neratinib) tablets, for oral use
INDICATIONS AND USAGE: NERLYNX is a kinase inhibitor indicated:
CONTRAINDICATIONS: None
WARNINGS AND PRECAUTIONS:
ADVERSE REACTIONS: The most common adverse reactions (reported in ≥5% of patients) were:
To report SUSPECTED ADVERSE REACTIONS, contact Puma Biotechnology, Inc. at 1-844-NERLYNX (1-844-637-5969) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
DRUG INTERACTIONS:
USE IN SPECIFIC POPULATIONS:
For Full Prescribing Information, please click here.
By clicking this link, you will be leaving the NERLYNX website and will be redirected to another webpage.
This information is intended for US healthcare professionals. Please confirm you are a healthcare professional to continue.